scholarly journals Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome

2014 ◽  
Vol 20 (1) ◽  
pp. 111-117 ◽  
Author(s):  
Victoria T. Potter ◽  
Pramila Krishnamurthy ◽  
Linda D. Barber ◽  
ZiYi Lim ◽  
Michelle Kenyon ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Myelogenous Leukemia ◽  
Long Term Outcomes ◽  
Hematopoietic Stem ◽  
Acute Myelogenous ◽  
Reduced Intensity

scholarly journals Measurable residual disease-based strategy and reduced-intensity hematopoietic stem cell transplantation for acute myelogenous leukemia in children

2021 ◽  
Author(s):  
Akihisa Sawada ◽  
Sadao Tokimasa ◽  
Masahiro Yasui ◽  
Maho Sato ◽  
Kohei Higuchi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Residual Disease ◽  
Survival Rates ◽  
Myelogenous Leukemia ◽  
Hematopoietic Stem ◽  
Acute Myelogenous ◽  
Measurable Residual Disease ◽  
Reduced Intensity

Background. Measurable residual disease (MRD) is a powerful prognostic factor in patients with acute myelogenous leukemia (AML). We previously conducted a prospective study on an MRD-based strategy for the treatment of children with AML, and its significance has been reported. The present retrospective study is a pooled analysis of 34 patients who were registered after the completion of the previous study. Procedure. Reduced-intensity conditioning (RIC) followed by allogeneic hematopoietic stem cell transplantation (RIC-HSCT) was adopted to increase survival rates and minimize toxicities. The strategy was also refined with a minor modification, with WT1 expression levels in peripheral blood, as an MRD marker after a 2nd course of chemotherapy (consolidation course 1), being measured in addition to WT1, chimeric mRNA, and aberrant surface markers in bone marrow. Results. Five-year relapse-free and overall survival rates were 76.5 and 85.2%, respectively. RIC-HSCT was safely and effectively performed on MRD-positive patients. Among patients who underwent RIC-HSCT, re-emerging/rising MRD and high levels of MRD before HSCT were risk factors for disease relapse early after HSCT. Conclusions. The MRD-based strategy and RIC-HSCT worked well for children with AML. HLA-haploidentical peripheral blood transplantation following RIC may be a promising candidate for further study on patients at very high risk of relapse.

Sign in / Sign up

Export Citation Format

Share Document